Figure 7 | Scientific Reports

Figure 7

From: A new method for pharmaceutical compounding and storage of anti-VEGF biologics for intravitreal use in silicone oil-free prefilled plastic syringes

Figure 7

Binding properties to VEGF. Binding to VEGF in ELISA for titrated amounts (1000–0.5 ng/mL) of (a) ranibizumab, (b) aflibercept, and (c) bevacizumab at D0 (black) and D7 (blue). Comparison of binding to VEGF at D0 and D7 for the following concentrations: ranibizumab 74 ng/mL (d) and 12.34 ng/mL for aflibercept (e) and bevacizumab (f). For each sample set n = 6. The unpaired Student’s t-test was used for statistical analysis.

Back to article page